Second- and third-line treatment strategies in multiple myeloma: a referral-center experience
Explore this paper's citation graph
Summary
Over the last two decades, more patients were treated with newer agents and triplets for relapsed MM, and the landscape of regimens has become more diverse, and survival after the first relapse is continually improving.
- Type
- article
- Published
- 2022-12-01
- Cited by
- 10
- References
- 23
- Access
- Open access
- OpenAlex
- https://openalex.org/W4311587513
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:254248841
Keywords
Multiple myeloma, Referral, Medicine, Center (category theory), Internal medicine
References
- Treatment of relapsed and refractory multiple myeloma
- Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients
- An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma.
- Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.
- Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02.
- Revised International Staging System for Multiple Myeloma: a report from IMWG
- Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.
- Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma.
- Progress in Myeloma - A Monoclonal Breakthrough.
- Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib.
- Heterogeneity of Second‐Line Treatment for Patients With Multiple Myeloma in the Connect MM Registry (2010–2016)
- Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR
- Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4‐year follow‐up and analysis of relative progression‐free survival from the randomized ELOQUENT‐2 trial
- Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
- Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management
- Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study.
- Multiple myeloma current treatment algorithms
- Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group.
- Multiple myeloma.
- Right‐sided non‐recurrent laryngeal nerve without any vascular anomaly: an anatomical trap
Cited by
- Contextual Causal Bayesian Optimisation
- Clinical Outcomes and Serum B-Cell Maturation Antigen Levels in a Real-World Unselected Population of Newly Diagnosed Multiple Myeloma Patients
- Pomalidomide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Survival and Subgroup Analyses From the OPTIMISMM Trial
- Outcomes of triple-class refractory multiple myeloma patients at a single clinic: A retrospective study.
- Belantamab Mafodotin Plus Proteasome Inhibition Efficacy Versus Comparators in Early Relapsed Myeloma: A Systematic Review and Network Meta‐Analysis
- Management of relapsed multiple myeloma: A British Society of Haematology and UK Myeloma Society guideline
- Design and Development of DNA Damage Chemical Inducers of Proximity for Targeted Cancer Therapy.
- Daratumumab-based second line therapy improves outcomes after VRD induction, upfront autologous transplant and lenalidomide maintenance
- Choosing Wisely in First Relapse of Multiple Myeloma: Expert Insights on Treatment Selection.
- Engineering TCR-directed T-cells for the treatment of multiple myeloma
Related papers
- [The referral system: a study on relations between general practitioners and specialists].
- Understanding variation in rates of referral among general practitioners: are inappropriate referrals important and would guidelines help to reduce rates?
- Impacting Factors to Implementation of the Two-way Referral System
- Evaluation of the Referral System Performance in the Family Physician Program
- Primary care physician referral patterns in Ontario, Canada: a descriptive analysis of self-reported referral data
- Family physicians' referral decisions: results from the ASPN referral study.
- Compliance with professional guidelines with reference to familial cancer services
- Knowledge, Attitudes and Referral Patterns of Lynch Syndrome: A Survey of Clinicians in Australia
- Attitudes and habits of chiropractors concerning referral to other health care providers.
- The role of physicians in mammography referral for older Caribbean women in Canada.